BioFocus and Ono sign CNS drug discovery agreement

BioFocus will use its drug discovery platform to deliver leads and clinical candidates

BioFocus, the service division of clinical stage biotechnology company Galapagos, has signed a new collaboration agreement with Japanese r&d company Ono focused on discovering novel drugs in the field of CNS disorders.

Under the new agreement, BioFocus will use its drug discovery platform to deliver leads and clinical candidates for its client. Financial details were not disclosed.

‘We are delighted to have this new agreement, which is the first drug discovery programme with this client,’ said Dr Chris Newton, svp Galapagos Services and managing director of BioFocus. ‘This project plays to BioFocus’s historic strengths and the expanding breadth and depth of this partnership is testament to a tried and trusted relationship.’

Dr Kazuhito Kawabata, member of the Board of Directors, executive officer and executive director, discovery and research of Ono, added: ‘This collaboration will strengthen Ono's drug discovery capability in the field of CNS disorders with significant unmet medical needs and we are expecting that innovative drugs will be created through this collaboration.’

Companies